- Home
- OM vs CLNN Comparison
OM vs CLNN Comparison
Compare OM & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OM | CLNN |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | 79 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.7M | 85.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | OM | CLNN |
|---|---|---|
| Price | $4.04 | $5.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $13.33 | ★ $33.75 |
| AVG Volume (30 Days) | ★ 175.7K | 99.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,476,000.00 | N/A |
| Revenue This Year | $9.29 | $17.64 |
| Revenue Next Year | $10.99 | $19,516.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.09 | N/A |
| 52 Week Low | $3.00 | $3.25 |
| 52 Week High | $21.36 | $13.50 |
Technical Indicators
Market Signals| Indicator | OM | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 42.85 | 48.11 |
| Support Level | $3.18 | $5.46 |
| Resistance Level | $4.88 | $6.71 |
| Average True Range (ATR) | 0.40 | 0.39 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 0.00 | 48.28 |
Price Performance
Historical ComparisonAbout OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.